Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3971008 | 0.83 | ALDH1A1 (0.50) | MEN1ALDH1A1HSP90AA1CYP2C9HPGD | |
| SCHEMBL3477837 | 0.81 | MEN1 (0.37) | MEN1ALDH1A1HSP90AA1CYP2C9HPGD | |
| SCHEMBL743427 | 0.77 | ALDH1A1 (0.39) | MEN1ALDH1A1HSP90AA1CYP2C9HPGD | |
| SCHEMBL127303 | 0.77 | ALDH1A1 (0.39) | MEN1ALDH1A1HSP90AA1CYP2C9HPGD | |
| SCHEMBL11888084 | 0.74 | KDM1A (0.38) | MEN1ALDH1A1HPGDKMT2AL3MBTL1 | |
| SCHEMBL3474315 | 0.73 | KDM4E (0.35) | ALDH1A1MAPT | |
| SCHEMBL9638465 | 0.73 | ALDH1A1 (0.52) | MEN1ALDH1A1HPGDKMT2AMAPT | |
| SCHEMBL17928551 | 0.66 | ALDH1A1 (0.46) | ALDH1A1HPGDMAPT | |
| SCHEMBL21102735 | 0.65 | ALDH3A1 (0.43) | MEN1ALDH1A1HSP90AA1CYP2C9HPGD | |
| SCHEMBL24462884 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430007-B1 | METHODS OF CHEMICAL SYNTHESIS OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INVOLVING THE USE OF PERSULFATE OXIDANTS | WISTA LAB LTD (SG) | 2014-02-12 | — | — | EP | disclosed |
| US-8227459-B2 | Diamino-phenothiazinyl derivatives as antiviral treatments | PROSETTA ANTIVIRAL INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227459-B2 | Diamino-phenothiazinyl derivatives as antiviral treatments | PROSETTA ANTIVIRAL INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20110178071-A1 | Antiviral Treatments | PROSETTA CORPORATION | 2011-07-21 | — | — | US | disclosed |
| US-20110178071-A1 | Antiviral Treatments | PROSETTA CORPORATION | 2011-07-21 | — | — | US | disclosed |
| WO-2010130977-A1 | METHODS OF CHEMICAL SYNTHESIS OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INVOLVING THE USE OF PERSULFATE OXIDANTS | WISTA LABORATORIES LTD. (SG) | 2010-11-18 | — | — | WO | disclosed |
| WO-2009047534-A2 | FUSED PHENOTHIAZINIUM COMPOUNDS, PREPARATION METHOD THEREOF AND USE AS PHOTOANTIMICROBIALS | PHARMALUCIA LTD (GB) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178071-A1 | Antiviral Treatments | HAVCR2, MAVS, EIF2AK2 | MEN1 4500/4885ALDH1A1 984/4885HSP90AA1 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.